IRB #

STUDY00020759

Title

A Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma

Principal Investigator

Sarah Nagle

Study Purpose

The purpose of the study is to learn about the safety and efficacy of CTX120, a study T cell product (not approved by the Food and Drug Administration) made from genetically modified allogeneic T cells , in patients with relapsed or refractory multiple myeloma.

Medical Condition(s)

Relapsed or refractory multiple myeloma

Eligibility Criteria

- 18 years or older
- Diagnosis of relapsed or refractory multiple myeloma
- Adequate organ function
- No prior allogeneic stem cell transplant
- No prior gene therapy or genetically modified cell therapy

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

5 years

Minors Included

No

Contact

Knight Cancer Intake Center: (503) 494-7999
Clinical Trials Information Line: (503) ­494-­1080 or trials@ohsu.edu

Sponsor

CRISPR Therapeutics

Recruitment End

01/01/2025

Compensation Provided

No


Go Back